Wed. 22 May 2024, 8:09am ET
Benzinga
Biotech, News, General
- Two abstracts highlighting the Company's lead hepatitis B-focused asset will be presented as poster and oral presentations.
- More mature interim data to be presented at EASL following abstract data cuts earlier in the year may indicate potential rates of functional cure.